Open Call: Strep A/Rheumatic Heart Disease Vaccine Development
Supports research and development to accelerate Strep A vaccines and prevent rheumatic heart disease, funding impactful projects across the vaccine pipeline, especially in high-burden regions.
Funder: Coefficient Giving
Due Dates: Rolling (Expressions of Interest accepted at any time)
Funding Amounts: No fixed limits; past grants range from ~$300K to >$10M; $200M fund target over five years.
Summary: Supports research and development to accelerate Strep A vaccines and prevent rheumatic heart disease, with a focus on impactful projects across the vaccine pipeline.
Key Information: Highly competitive (1–2% of unsolicited proposals funded); strong alignment with program priorities required.
Description
The Strep A Vaccine Fund, managed by Coefficient Giving, is a multi-donor initiative dedicated to accelerating the development of vaccines targeting Streptococcus A (Strep A), with the primary goal of preventing rheumatic heart disease (RHD). The fund supports projects across the entire vaccine development pipeline—from early-stage scientific research and preclinical models to clinical trials, regulatory preparation, and near-term interventions for RHD reduction. Funding priorities include advancing vaccine candidates through early clinical development (such as Phase 1 and controlled human infection model trials), strengthening foundational science (epidemiology, immunology, preclinical models), developing next-generation vaccine candidates, and preparing for regulatory approval and policy recommendations, particularly in low- and middle-income countries where RHD burden is highest.
